JAK & TYK2
Input Form
Complete all sections for the most accurate small molecule recommendation.
Condition
Select the primary diagnosis
Patient profile
Demographics and baseline
Increases MACE risk with systemic JAK inhibitors
Increases MACE risk with JAK inhibitors
Disease characteristics
Current disease burden
Safety screening
Black box warning risk factors — check all that apply
✓
Cardiovascular disease / prior MACE
Contraindicates systemic JAK inhibitors
✓
Prior or active malignancy
BBW concern — avoid systemic JAK inhibitors
✓
Prior DVT / PE / thrombosis
Strongest contraindication for JAK inhibitors
✓
Pregnancy / planning pregnancy
Avoid all systemic JAK/TYK2 inhibitors
✓
Recurrent serious infections
BBW concern for all systemic JAK inhibitors
✓
Latent TB / TB exposure
Screen and treat before initiating
✓
Hepatitis B (active or prior)
Reactivation risk — antiviral prophylaxis
✓
Severe renal impairment (eGFR <30)
Dose adjustment or avoidance required
✓
Immunocompromised
Contraindicates ruxolitinib cream (AD indication)
✓
IBD (Crohn's or UC)
Upadacitinib and tofacitinib approved for IBD
✓
Low platelets / thrombocytopenia
Abrocitinib-specific concern
✓
Severe hepatic impairment
Avoid tofacitinib; caution with others
Treatment history
Prior treatments for this condition
Add each agent tried and reason for stopping
Practical factors
Access and preference
Applicable options
Updates live as you complete the form
Complete the form above — applicable agents will appear here as you make selections.
Complete the form above to generate a personalized JAK/TYK2 recommendation with safety alerts.
Not a substitute for clinical judgment or institutional prescribing guidelines.